ECM
XENE icon

Endurant Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Endurant Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-62,743
Closed -$959K – 80
2021
Q3 		$959K Buy
+62,743
New +$1.09M 0.22% 50
2017
Q2 		– Sell
-340,672
Closed -$1.36M – 101
2017
Q1 		$1.36M Buy
+340,672
New +$2.68M 0.44% 59

Other funds holding XENE

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Endurant Capital Management's XENE Position: Q4 2021 in Review

Endurant Capital Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2021, closing a stake of 62,743 shares — an estimated $959K sold.

Endurant Capital Management first reported a position in XENE in Q1 2017 and held it in 2 quarters. The position peaked at $1.36M in Q1 2017. 130 funds tracked by Wall St. Rank hold XENE as of Q4 2021.

  • Endurant Capital Management reported no remaining Xenon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Endurant Capital Management sold 62,743 Xenon Pharmaceuticals shares in Q4 2021, an estimated $959K.
  • Endurant Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • Endurant Capital Management's Xenon Pharmaceuticals position peaked at $1.36M in Q1 2017.
  • 130 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2021.

Based on Endurant Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.